single-hyaluronic-acid-injection-matches-three-dose-therapy-for-knee-osteoarthritis
Single Hyaluronic Acid Injection Matches Three-Dose Therapy for Knee Osteoarthritis

Single Hyaluronic Acid Injection Matches Three-Dose Therapy for Knee Osteoarthritis

A single intra-articular injection of crosslinked hyaluronic acid matched the therapeutic performance of a three-injection regimen for knee osteoarthritis, according to a randomized, double-blind, multicenter noninferiority study published in the Journal of Orthopaedic Surgery and Research. The clinical trial compared the efficacy and safety of LBSA0103, known as Synovian, against three weekly injections of Synvisc in Chinese patients managing mild to moderate knee osteoarthritis.

The evaluated formulation, LBSA0103, is a high molecular weight intra-articular hyaluronic acid product crosslinked with 1,4-butanediol diglycidyl ether, or BDDE.

Investigators enrolled 265 patients diagnosed with knee osteoarthritis across multiple study sites. Participants were randomly assigned to receive either three injections of Synvisc or a three-injection course of LBSA0103 that incorporated two sham injections. All administrations took place at weekly intervals.

Following the final injection, patients attended clinical follow-up visits at one week, six weeks, 13 weeks, and 26 weeks. The primary outcome was the change in WOMAC-Likert pain score from baseline to 13 weeks after the last injection. To establish noninferiority between the single-dose formulation and the three-injection comparator, researchers established a prespecified noninferiority margin of 1.6 points on the WOMAC-Likert pain scale.

At 13 weeks after the last injection, both treatment groups achieved marked reductions in joint pain. The WOMAC-Likert pain scores decreased from baseline by -7.33 points in the LBSA0103 group and by -6.76 points in the Synvisc group. The upper limit of the 97.5% confidence interval remained below the predefined 1.6 margin, successfully confirming the noninferiority of single-injection LBSA0103 relative to the three-injection Synvisc regimen.

Researchers also evaluated several secondary endpoints across the follow-up visits to assess broader physical and functional outcomes. These included WOMAC-Likert subscale and total scores, global evaluations conducted independently by patients and investigators, physical examinations, knee range of motion, and the proportion of patients requiring rescue medications. Additionally, investigators evaluated response rates according to Outcome Measures in Rheumatology and Osteoarthritis Research Society International (OMERACT-OARSI) standards.

Tracking across all follow-up visits consistently indicated general clinical improvement in both treatment groups across secondary measures. For most secondary endpoints, researchers identified no statistically significant differences between the two cohorts. Significant differences between the groups were observed from baseline to 26 weeks after the final injection, specifically in the WOMAC-Likert pain score, the investigator’s global assessment, and the range of motion assessment in the affected knee.

Safety assessments demonstrated that the safety profiles of both treatment groups were comparable, with no new safety issues identified during the trial. The authors concluded that a single injection of BDDE-crosslinked LBSA0103 is noninferior to three weekly injections of Synvisc, supporting LBSA0103 as a safe and effective therapeutic option for Chinese patients with mild to moderate knee osteoarthritis. The clinical trial was registered at www.chictr.org.cn under identifier ChiCTR2400090323 on September 27, 2024.

Subject of Research: Hyaluronic acid injection regimens for knee osteoarthritis

Article Title: Efficacy and safety of a single-injection BDDE-crosslinked hyaluronic acid versus a three-injection hyaluronic acid for knee osteoarthritis: a multicenter, double-blind, randomized, noninferiority study

Article References: Feng, H., Guan, Z., Xue, Q., Zhang, W., Liu, L., Yang, Y., Zhu, Z., Gao, G., Dai, B., Guo, S., Li, Y., & Cai, H. (2026). Efficacy and safety of a single-injection BDDE-crosslinked hyaluronic acid versus a three-injection hyaluronic acid for knee osteoarthritis: a multicenter, double-blind, randomized, noninferiority study. Journal of Orthopaedic Surgery and Research. https://doi.org/10.1186/s13018-026-07397-9

Image Credits: AI Generated

DOI: 10.1186/s13018-026-07397-9

Keywords: knee osteoarthritis, hyaluronic acid, intra-articular injection, LBSA0103, Synovian, Synvisc, BDDE crosslinking, noninferiority trial, WOMAC pain score, randomized controlled trial, orthopedic surgery, joint lubrication, OMERACT-OARSI, range of motion, sham injections, double-blind study